Business
Karyopharm Announces XPOVIO® (selinexor) Clinical Data to be Presented at European Society for Medical Oncology Virtual Congress 2020
NEWTON, Mass., Sept. 14, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"NEWTON, Mass., Sept. 14, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that four abstracts have been selected for poster presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 taking place from September 19-21. Three abstracts from investigator-sponsored studies will feature clinical data related to XPOVIO (selinexor), the Company's first in class, oral Selective Inhibitor of Nuclear Export (SINE) compound, including: (i) combination data with pembrolizumab for the treatment of melanoma, (ii) combination data with carboplatin and paclitaxel for the treatment of advanced or metastatic solid tumors, and (iii) combination data with topotecan for the treatment of advanced or metastatic solid tumors. A fourth abstract highlights the use of machine learning algorithms to investigate characteristics associated with XPOVIO tolerability and efficacy.\n\"We are excited to share additional clinical data from multiple XPOVIO studies at ESMO this year, further highlighting XPOVIO's potential application in solid tumors, an important area for future pipeline expansion,\" said Sharon Shacham, PhD, MBA, Founder, President and Chief Scientific Officer of Karyopharm. \"We are particularly encouraged by data from the Phase 1b study of XPOVIO in combination with pembrolizumab, which showed significant clinical activity as frontline therapy compared to historic frontline single-agent pembrolizumab in patients with metastatic non-uveal melanoma. In addition, XPOVIO in combination with carboplatin and paclitaxel conferred appreciable clinical activity with durable objective responses, providing an opportunity for further exploration in tumor types where carboplatin and paclitaxel chemotherapy is used as the standard of care. The encouraging results from these combination studies warrant further research into the potential utility of XPOVIO in solid tumors.\"\nDetails for the ESMO poster presentations are as follows:\nTitle: Phase 1b study to evaluate the safety of selinexor (KPT-330) in combination with pembrolizumab in patients with advanced malignancies - the melanoma experiencePresenter: Isabella C. Glitza Oliva, MD Anderson Cancer CenterPresentation Number: 1124PDate: Available on demand on Thursday, Sept...